Meeting
2022 ASCO Genitourinary Cancers Symposium
Underutilization of standard of care (SOC) treatment intensification in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) by specialty.
Authors
Umang Swami
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
Umang Swami , Agnes Hong , Nader N. El-Chaar , David Nimke , Krishnan Ramaswamy , Brandon Diessner , Rickard Sandin , Neeraj Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Other
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 183)
DOI
10.1200/JCO.2022.40.6_suppl.183
Abstract #
183
Poster Bd #
P2
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Evaluation of tumor genomic variants in Japanese patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide: Protocol of a phase 4 study (CUARTET).
First Author: Hirotsugu Uemura
Poster
2022 ASCO Genitourinary Cancers Symposium
Evolving real-world patterns of practice in metastatic castration-sensitive prostate cancer (mCSPC): The genitourinary research consortium (GURC) national multicenter cohort study.
First Author: Steven Yip
Poster
2018 Genitourinary Cancers Symposium
Phase II randomized study of abiraterone acetate plus ADT versus apalutamide versus abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels. (LACOG 0415).
First Author: Fernando C. Maluf
Poster
2018 Genitourinary Cancers Symposium
Real-world experience with docetaxel for castration-sensitive prostate cancer from a population-based analysis.
First Author: Jean-Michel Lavoie